SAN DIEGO, Oct. 20 Hollis-Eden Pharmaceuticals (Nasdaq: HEPH) has retained Burrill LLC to provide exclusive strategic advisory services, with an initial focus on partnering Hollis-Eden's lead program Apoptone, currently in Phase I/II development for hormone-refractory prostate cancer.
Advertisement
"We are very pleased to collaborate with Burrill & Company given their experience in successfully executing life science transactions," said James Frincke, Ph.D. CEO of Hollis-Eden Pharmaceuticals. Benjamin Chen, Ph.D., Managing Director at Burrill LLC added: "We look forward to assisting Hollis-Eden now that they have refocused their business strategy on the advancement of the lead compounds from their extensive library of synthetic steroid analogs."
Advertisement
About Hollis-Eden Pharmaceuticals
Hollis-Eden Pharmaceuticals is a development-stage company with two candidates in clinical trials: Apoptone® (HE3235), in the dose-escalation portion of a Phase I/II trial of patients with late-stage prostate cancer, and Triolex®, in a Phase IIa trial in obese type 2 diabetes mellitus patients. Apoptone® and Triolex® represent the lead candidates from Hollis-Eden's small molecule platform based on metabolites or synthetic analogs of endogenous steroid hormones. For more information on Hollis-Eden, please visit www.holliseden.com
About Burrill & Company
Founded in 1994, Burrill & Company is a San Francisco-based global leader in life sciences with activities in Venture Capital, Private Equity, Merchant Banking and Media. The Burrill family of venture capital funds has over $1 billion under management and its merchant banking business is one of the industry leaders in life sciences transactions. Burrill is also the creator, sponsor and facilitator of over a dozen leading industry conferences worldwide and publisher of a range of bio-intelligence reports including the Burrill Report, which tracks the progress of the global biotechnology industry and annual "State of the Industry" report. For more information, visit http://www.burrillandco.com.
This press release contains forward-looking statements within the meaning of the federal securities laws concerning, among other things, the potential and prospects of Hollis-Eden Pharmaceuticals, Inc. regaining and maintaining compliance with the listing standards of the NASDAQ Global Market and its drug discovery program and its drug candidates. Any statement included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause Hollis-Eden's actual results to differ materially from historical results or those expressed or implied by such forward-looking statements. Such statements are subject to certain risks and uncertainties inherent in the Company's business, including, but not limited to: the ability to complete preclinical and clinical trials successfully and within specified timelines, if at all; the ability to obtain regulatory approval for TRIOLEX(®) (HE3286), APOPTONE(®) (HE3235) or any other investigational drug candidate; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, Hollis-Eden undertakes no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.
SOURCE Hollis-Eden Pharmaceuticals
